Domantis Limited
Brentford, GB· latest recorded location
Domantis Limited is named on 38 US grants and 55 published applications in this corpus. Its most frequent classification is C07K (Peptides).
- Granted patents
- 38
- Published applications
- 55
- Inventors
- 74
- Granted in 2026 so far
- 0
- Most recent grant
- 18 Jun 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 1 | 3 |
| 2009 | 1 | 7 |
| 2010 | 3 | 10 |
| 2011 | 2 | 5 |
| 2012 | 2 | 2 |
| 2013 | 5 | 7 |
| 2014 | 5 | 3 |
| 2015 | 3 | 2 |
| 2016 | 3 | 1 |
| 2017 | 3 | 4 |
| 2018 | 2 | 2 |
| 2019 | 1 | 2 |
| 2020 | 1 | 1 |
| 2021 | 3 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
By publication year.
Technology areas
Share of 93 documents
Recent patents
- Compositions monovalent for CD28 binding and methods of use18 Jun 2024US 12,012,452 B2
- Antibody polypeptides that antagonize CD40L23 Nov 2021US 11,180,567 B2
- Methods of treating immune diseases by administering antibody polypeptides that antagonize CD405 Oct 2021US 11,136,406 B2
- Compositions monovalent for CD28 binding and methods of use16 Feb 2021US 10,919,965 B2
- Nucleic acids encoding antibody polypeptides that antagonize CD4028 Jan 2020US 10,544,228 B2
- Antibody polypeptides that antagonize cd40l10 Mar 2022US 2022/0073636 A1
- Compositions monovalent for cd28 binding and methods of use18 Feb 2021US 2021/0047414 A1
- Methods of treating immune diseases by administering antibody polypeptides that antagonize cd4025 Jun 2020US 2020/0199244 A1
- Antibody polypeptides that antagonize cd40l4 Apr 2019US 2019/0100595 A1
- Polypeptides, antibody variable domains & antagonists7 Feb 2019US 2019/0040148 A1
Most cited
By later US patents
- Methods for selecting functional polypeptides179US 6,696,245 B22004
- Method to screen phage display libraries with different ligands66US 6,846,634 B12005
- Bispecific fusion antibodies with enhanced serum half-life33US 8,921,528 B22014
- Monovalent anti-CD40L antibody polypeptides and compositions thereof32US 7,563,443 B22009
- Antibody polypeptides that antagonize CD4024US 9,475,879 B22016